We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the four trailing quarters, the average surprise being 1.5%.
The Zacks Consensus Estimate for the top line is currently pegged at $3.7 billion, up 1.1% from the year-ago quarter. The growth in revenues is likely to have been due to an uptick in demand of clients, strategic acquisitions and expansion of lab business.
Our estimate for revenues from the Technology and Analytics segment is currently pegged at $1.5 billion, up 2% from the year-ago quarter. The uptick is likely to have been due to new clients added to the Orchestrated Customer Engagement technology platform and the launch of a new software platform that tracks the performance of 1.6 million drugs covering 600 diseases across 93 countries.
Our estimate for the Research and Development segment’s revenues is currently pegged at $2 billion, up 1% from the year-ago reported figure. The growth is likely to have been due to the strategic acquisitions that offer clinical research coordination study feasibility and capability of patient recruitment. Expansion of lab business is likely to have aided this segment’s growth as well. Our estimate for Contract sales and Medical solutions’ revenues is pegged at $178.2 million, indicating a 2.1% decline from the year-ago figure.
The consensus estimate for earnings per share is pegged at $2.5, indicating marginal year-over-year growth. The company is expected to have benefited from cost management discipline.
Our estimate for adjusted EBITDA for the first quarter is pegged at $854.4 million, implying marginal growth from the year-ago figure.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for VRSK this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV currently has an Earnings ESP of 0.00% and a Zacks Rank of 3.
Stocks to Consider
Here are a few stocks from the broader Business Services sector, which according to our model, have the right combination of elements to beat earnings this season.
Charles River Associates (CRAI - Free Report) : The Zacks Consensus Estimate for first-quarter fiscal revenues is pegged at $160.7 million, indicating growth of 5.1% from the year-ago quarter. For earnings, the consensus mark is pegged at $1.4 per share, up 7.8% year over year. CRAI beat the consensus estimate in two of the past four quarters and missed on the other two instances. It has an earnings surprise of 8.1%, on average.
Fidelity National (FIS - Free Report) : The Zacks Consensus Estimate for first-quarter revenues is pegged at $2.5 billion, indicating a decline of 30.3% from the year-ago quarter. For earnings, the consensus mark is pegged at 96 cents per share, indicating a 25.6% decline from the year-ago quarter. FIS beat the consensus estimate in two of the past four quarters and missed on the other two instances. It has a negative surprise of 7.4%, on average.
FIS currently has an Earnings ESP of +10.8% and a Zacks Rank of 3. It is scheduled to declare its first-quarter 2024 results on May 6.
Nu (NU - Free Report) : The Zacks Consensus Estimate for first-quarter revenues is pegged at $2.5 billion, indicating a decline of 55.2% from the year-ago quarter. For earnings, the consensus mark is pegged at 9 cents per share, indicating a rise of more than 100% from the year-ago quarter. NU beat the consensus estimate in three of the past four quarters and missed on one instance. It has an average surprise of 22.2%, on average.
NU currently has an Earnings ESP of +3.85% and a Zacks Rank of 3. It is scheduled to declare its first-quarter 2024 results on May 20.
Image: Bigstock
IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?
IQVIA Holdings, Inc. (IQV - Free Report) is scheduled to release its first-quarter 2024 results on May 2, before market open.
IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the four trailing quarters, the average surprise being 1.5%.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
Q1 Expectations
The Zacks Consensus Estimate for the top line is currently pegged at $3.7 billion, up 1.1% from the year-ago quarter. The growth in revenues is likely to have been due to an uptick in demand of clients, strategic acquisitions and expansion of lab business.
Our estimate for revenues from the Technology and Analytics segment is currently pegged at $1.5 billion, up 2% from the year-ago quarter. The uptick is likely to have been due to new clients added to the Orchestrated Customer Engagement technology platform and the launch of a new software platform that tracks the performance of 1.6 million drugs covering 600 diseases across 93 countries.
Our estimate for the Research and Development segment’s revenues is currently pegged at $2 billion, up 1% from the year-ago reported figure. The growth is likely to have been due to the strategic acquisitions that offer clinical research coordination study feasibility and capability of patient recruitment. Expansion of lab business is likely to have aided this segment’s growth as well. Our estimate for Contract sales and Medical solutions’ revenues is pegged at $178.2 million, indicating a 2.1% decline from the year-ago figure.
The consensus estimate for earnings per share is pegged at $2.5, indicating marginal year-over-year growth. The company is expected to have benefited from cost management discipline.
Our estimate for adjusted EBITDA for the first quarter is pegged at $854.4 million, implying marginal growth from the year-ago figure.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for VRSK this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV currently has an Earnings ESP of 0.00% and a Zacks Rank of 3.
Stocks to Consider
Here are a few stocks from the broader Business Services sector, which according to our model, have the right combination of elements to beat earnings this season.
Charles River Associates (CRAI - Free Report) : The Zacks Consensus Estimate for first-quarter fiscal revenues is pegged at $160.7 million, indicating growth of 5.1% from the year-ago quarter. For earnings, the consensus mark is pegged at $1.4 per share, up 7.8% year over year. CRAI beat the consensus estimate in two of the past four quarters and missed on the other two instances. It has an earnings surprise of 8.1%, on average.
CRAI currently has an Earnings ESP of +0.54% and a Zacks Rank of 1. It is scheduled to declare its first-quarter 2024 results on May 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Fidelity National (FIS - Free Report) : The Zacks Consensus Estimate for first-quarter revenues is pegged at $2.5 billion, indicating a decline of 30.3% from the year-ago quarter. For earnings, the consensus mark is pegged at 96 cents per share, indicating a 25.6% decline from the year-ago quarter. FIS beat the consensus estimate in two of the past four quarters and missed on the other two instances. It has a negative surprise of 7.4%, on average.
FIS currently has an Earnings ESP of +10.8% and a Zacks Rank of 3. It is scheduled to declare its first-quarter 2024 results on May 6.
Nu (NU - Free Report) : The Zacks Consensus Estimate for first-quarter revenues is pegged at $2.5 billion, indicating a decline of 55.2% from the year-ago quarter. For earnings, the consensus mark is pegged at 9 cents per share, indicating a rise of more than 100% from the year-ago quarter. NU beat the consensus estimate in three of the past four quarters and missed on one instance. It has an average surprise of 22.2%, on average.
NU currently has an Earnings ESP of +3.85% and a Zacks Rank of 3. It is scheduled to declare its first-quarter 2024 results on May 20.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.